NI
67
4
ES
56
8
XRX
55
3
K
62
2
SRE
56
7
DIS
68
3
SCHW
49
4
HES
62
6
TEL
68
2
HCP
70
4
GT
56
5
QRVO
47
-5
AVY
65
-3
XOM
48
6
CMG
50
-13
DE
56
3
SYF
71
4
FLS
63
-6
V
42
4
AVGO
69
-7
NI
67
4
ES
56
8
XRX
55
3
K
62
2
SRE
56
7
DIS
68
3
SCHW
49
4
HES
62
6
TEL
68
2
HCP
70
4
GT
56
5
QRVO
47
-5
AVY
65
-3
XOM
48
6
CMG
50
-13
DE
56
3
SYF
71
4
FLS
63
-6
V
42
4
AVGO
69
-7
Financhill
Back

Marinus Pharmaceuticals Quote, Financials, Valuation and Earnings

Wall St Issues Rare "SELL" alert

MarketBeat is making the full list completely FREE for a limited time.
Sell
41

MRNS
Marinus Pharmaceuticals

Last Price:
1.84
Seasonality Move:
2.77%

7 Day Trial

ALL ACCESS PASS

$ 7

AI Tech Innovator Poised for Strategic Buyouts Invest Now

Learn More

Marinus Pharmaceuticals Price Quote

$1.84

Marinus Pharmaceuticals Key Stats

Sell
41
Marinus Pharmaceuticals (MRNS) is a Sell
Day range:
$1.72 - $1.86
52-week range:
$1.05 - $11.26
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
3.41
P/B ratio:
0%
Volume:
568.9K
Avg. volume:
544.5K
1-year change:
-77%
Market cap:
$101.4M
Revenue:
$31M
EPS:
$-2.66

How Much Does Marinus Pharmaceuticals Make?

Is Marinus Pharmaceuticals Growing As A Company?

Marinus Pharmaceuticals Stock Price Performance

What Is Marinus Pharmaceuticals 52-Week High & Low?

Marinus Pharmaceuticals Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Marinus Pharmaceuticals?

Is Marinus Pharmaceuticals Cash Flow Positive?

  • What Is MRNS Cash Flow From Operations?
    Cash flow from operations (TTM) is -$120.5M
  • What Is Marinus Pharmaceuticals’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $9.1M
  • What Is Marinus Pharmaceuticals’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $48.2M

Marinus Pharmaceuticals Return On Invested Capital

  • Is Management Doing A Good Job?
    MRNS return on invested capital is -180.94%
  • What Is Marinus Pharmaceuticals Return On Assets?
    ROA measures how assets are converting to revenues and is -93.58%
  • What Is MRNS Return On Equity?
    ROE is a measure of profitability and is -1150.43%

Marinus Pharmaceuticals Earnings Date & Stock Price

Marinus Pharmaceuticals Competitors

Marinus Pharmaceuticals Dividend Yield

Marinus Pharmaceuticals Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -8.86%
Revenue: 32.48% -15.26%

Analyst Recommendations

Buy Recommendations: 6
Hold Recommendations: 2
Sell Recommendations: 0
Price Target: 6.89
Upside from Last Price: 274.4%

Major Shareholders

  • How many MRNS shares are owned by institutional investors?
    65.2M MRNS shares are owned by institutional investors
  • How many MRNS shares are owned by insiders?
    1M MRNS shares are owned by insiders